Aura Biosciences, Inc.: ADAR1 Capital Management, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ADAR1 Capital Management disclosed a stake exceeding 5% in Aura Biosciences via a Schedule 13G filing with the SEC (accession 0001104659-26-128723). The exact share count and percentage were not specified in the filing headline. The move signals new institutional interest in the clinical-stage oncology company. Investors will watch for further detail on the position's size and any subsequent 13D or 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Aura Biosciences, Inc., ADAR1 Capital Management, LLC